Previous 10 | Next 10 |
aTyr Pharma (NASDAQ: LIFE ) +63% on Kyorin Pharma deal . More news on: aTyr Pharma, Inc., Town Sports International Holdings, Inc., Pulmatrix, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Cellectar Biosciences (NASDAQ: CLRB ) perks up 11% premarket on average volume in reaction to Orphan Drug designation in the U.S. for CLR 131 for slow-growing type of non-Hodgkin lymphoma called lymphoplasmacytic lymphoma (LPL). More news on: Cellecta...
FLORHAM PARK, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the U.S. Food and Drug Adm...
Dosing is underway in a Phase 2 registrational trial in China evaluating I-Mab Biopharma's TJ202/MOR202, a fully human monoclonal antibody targeting a protein found on the surface of cancer cells called CD38, in patients with relapsed/refractory multiple myeloma (MM). The company in-lice...
FLORHAM PARK, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president ...
30% overall response rate seen with an average progression free survival of 4.5 months and an acceptable and expected safety profile Additional data in patients receiving higher fractionated doses of CLR 131 anticipated in January FLORHAM PARK, N.J., Dec. 16, 2019 (GLOBE NEWSWIRE) -...
FLORHAM PARK, N.J., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced Jarrod Longcor, chief busines...
50% overall response rate in cohort of patients receiving fractionated 37.5 mCi/m 2 dose of CLR 131 31.3% overall response rate in multiple myeloma patients over all dose levels, including single bolus and fractionated doses of CLR 131 FLORHAM PARK, N.J., Dec. 09, 2019 (GL...
FLORHAM PARK, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced an oral presentation at the 6...
Gainers: Cancer Genetics CGIX +224% . More news on: Surface Oncology, Inc., Cellectar Biosciences, Inc., Magenta Therapeutics, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...